DHG Pharmaceutical JSCSTC:DHG 78 EV-to-FCF is 12.27 as of Jun. 30, 2026, which is 31% below its 10-year median of 17.89. GuruFocus rates STC:DHG with a GF Score™ of 78/100 and a GF Value™ of ₫113,390.11 (Modestly Undervalued). The stock has 4 warning signs investors should review. Among 558 Drug Manufacturers companies, DHG Pharmaceutical JSC ranks better than 69% on this metric.
EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, DHG Pharmaceutical JSC's Enterprise Value is ₫10,074,261 Mil.
DHG Pharmaceutical JSC's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 was ₫821,116 Mil. Therefore, DHG Pharmaceutical JSC's EV-to-FCF for today is 12.27.
The historical rank and industry rank for DHG Pharmaceutical JSC's EV-to-FCF or its related term are showing as below:
STC:DHG'
s EV-to-FCF Range Over the Past 10 Years
Min: -95.72 Med: 17.89 Max: 87.87
Current: 12.27
During the past 13 years, the highest EV-to-FCF of DHG Pharmaceutical JSC was 87.87. The lowest was -95.72. And the median was 17.89.
STC:DHG's EV-to-FCF is ranked better than 69% of 558
companies
in the Drug Manufacturers industry
Industry Median: 20.045
vs STC:DHG: 12.27
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
DHG Pharmaceutical JSC's PE Ratio (TTM) for today is calculated as:
DHG Pharmaceutical JSC's share price for today is ₫93800.00.
DHG Pharmaceutical JSC's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₫7011.000.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, DHG Pharmaceutical JSC's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
DHG Pharmaceutical JSC EV-to-FCF vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, DHG Pharmaceutical JSC's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where DHG Pharmaceutical JSC's EV-to-FCF falls into.
DHG Pharmaceutical JSC's current Enterprise Value is ₫10,074,261 Mil.
DHG Pharmaceutical JSC's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₫821,116 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
DHG Pharmaceutical JSC (STC:DHG) has a EV-to-FCF of 12.27 as of Jun. 30, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on DHG Pharmaceutical JSC and its competitors. This is 31% below median its historical median of 17.89. According to the industry distribution chart, DHG Pharmaceutical JSC ranks #173 out of 558 companies in the Drug Manufacturers industry, placing it in the top 31%.
Is DHG Pharmaceutical JSC's EV-to-FCF too high?
DHG Pharmaceutical JSC's current EV-to-FCF of 12.27 is 31% below median its 10-year median of 17.89. The Drug Manufacturers industry median EV-to-FCF is 20.05. DHG Pharmaceutical JSC's value of 12.27 is 38.8% below this industry median. Based on the distribution chart, DHG Pharmaceutical JSC ranks #173 out of 558 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, DHG Pharmaceutical JSC has a GF Score™ of 78/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does DHG Pharmaceutical JSC's EV-to-FCF compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, DHG Pharmaceutical JSC ranks #173 out of 558 companies for EV-to-FCF. This puts DHG Pharmaceutical JSC in the upper half of its industry. The industry median EV-to-FCF is 20.05. DHG Pharmaceutical JSC's value of 12.27 is 38.8% below this benchmark. While the company's 10-year median is 17.89 vs. the industry median of 20.05, DHG Pharmaceutical JSC has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Drug Manufacturers company?
The median EV-to-FCF among Drug Manufacturers companies is 20.05, based on 558 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. DHG Pharmaceutical JSC's current EV-to-FCF of 12.27 is 38.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on DHG Pharmaceutical JSC and its competitors. For the Drug Manufacturers industry, the median EV-to-FCF is 20.05 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. DHG Pharmaceutical JSC's current EV-to-FCF is 12.27, which is 31% below median its own 10-year median of 17.89. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is DHG Pharmaceutical JSC stock overvalued right now?
Based on GuruFocus' analysis, DHG Pharmaceutical JSC (STC:DHG) is currently considered Modestly Undervalued. The stock's GF Value™ is ₫113,390.11, compared to a current price of ₫93,800.00 — trading 17.3% below its estimated fair value. The current EV-to-FCF is 12.27, which is 31% below median its 10-year median of 17.89 and 38.8% below the Drug Manufacturers industry median of 20.05. DHG Pharmaceutical JSC's overall GF Score™ is 78/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For DHG Pharmaceutical JSC (STC:DHG), the current EV-to-FCF is 12.27 as of Jun. 30, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is DHG Pharmaceutical JSC (STC:DHG) Overvalued in 2026?
Based on GuruFocus' analysis, DHG Pharmaceutical JSC stock appears to be undervalued.
The current stock price of ₫93,800.00 is trading 17.3% below its estimated GF Value™ of ₫113,390.11.
GuruFocus considers DHG Pharmaceutical JSC to be Modestly Undervalued.
Key valuation signals for STC:DHG:
EV-to-FCF: 12.27 (31% below median its 10-year median of 17.89)
GF Value™: ₫113,390.11 vs. price of ₫93,800.00 (17.3% below fair value)
Industry Position: 38.8% below the Drug Manufacturers median (#173 of 558)
No single metric tells the full story. See the STC:DHG stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
DHG Pharmaceutical JSC produces and trades in pharmaceutical products. It provides various pharmaceutical products in the areas of antibiotics, antifungals, and antiparasitics; analgesics and antipyretics; ear-nose-throat, cough, and asthma; ophthalmic and nervous system; muscular and osteoarticular; digestive; hepatic; cardiovascular and diabetic; vitamins and minerals; and dermal and beauty care.
78GF Score
Get the complete analysis for STC:DHG
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STC:DHG has been successfully added to your 
